Heparin clearance during continuous veno-venous haemofiltration

Intensive Care Med. 1994;20(3):212-5. doi: 10.1007/BF01704703.

Abstract

Objective: To determine whether premature clotting of haemofiltration circuits could be related to heparin removal across the filter membrane into the ultrafiltrate.

Design: Randomised study using either unfractionated (n = 8) or low molecular weight (n = 7) heparin for anticoagulation of the haemofiltration circuit at 1000 and 600 U/h respectively. Samples were drawn at 1 and 2 h from arterial and venous limbs of the haemofilter circuit for measurement of plasma heparin (as anti-Factor Xa activity), antithrombin III and haematocrit. Ultrafiltrate samples were collected at the same time for measurement of anti-Xa activity.

Setting: Intensive care unit.

Patients: Patients in acute renal failure requiring haemofiltration.

Results: Both unfractionated and low molecular weight heparin plasma levels were within the range required for therapeutic anticoagulation in all but one patient at 2 h. Ultrafiltrate anti-Xa levels were insignificant. Antithrombin III levels in these critically ill patients were subnormal in 11 of the 15 studies.

Conclusions: Despite their small sizes, neither unfractionated nor low molecular weight heparins cross the haemofilter membrane into the ultrafiltrate in any measurable quantity. Both heparins were present in plasma at a level suitable for therapeutic anticoagulation. Subnormal levels of antithrombin III may be an important factor in determining filter longevity.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Acute Kidney Injury / blood*
  • Acute Kidney Injury / therapy*
  • Adult
  • Aged
  • Antithrombin III / analysis
  • Arteries
  • Blood
  • Critical Illness
  • Drug Monitoring
  • Factor Xa Inhibitors
  • Female
  • Hematocrit
  • Hemofiltration / methods*
  • Heparin / blood*
  • Heparin / classification
  • Heparin / pharmacokinetics*
  • Humans
  • Male
  • Metabolic Clearance Rate
  • Middle Aged
  • Molecular Weight
  • Time Factors
  • Veins

Substances

  • Factor Xa Inhibitors
  • Antithrombin III
  • Heparin